g-csf for mobilizing transplanted bone marrow stem cells in rat model of parkinson's disease

objective(s): granulocyte-colony stimulating factor (g-csf) is used in clinical practice for the treatment of neutropenia and to stimulate generation of hematopoietic stem cells in bone marrow donors. in the present study, the ability of g-csf in mobilizing exogenous bone marrow stem cells (bmscs) from peripheral blood into the brain was tested. we for the first time injected a small amount of bmscs through the tail vein. materials and methods: we choose 25 male wistar rats (200–250 g) were lesioned by 6-ohda injected into the left substantia nigra, pars compacta (snpc). g-csf (70 µg/kg/day) was given from the 7th day after lesion for five days. the bmscs (2×105) were injected through the dorsal tail vein on the 7th day after lesion. results:the number of rotations was significantly lower in the stem cell therapy group than in the control group. in the third test in the received g-csf and g-csf+stem cells groups, animals displayed significant behavioral recovery compared with the control group (p<0.05). there was a significant difference in the average of dopaminergic neurons in snpc between the control group and g-csf and g-cs+stem cells groups. we didn&apos;t detect any labeling stem cells in snpc. conclusion: g-csf can&apos;t mobilize low amounts of exogenous bmscs from the blood stream to injured snpc. but g-csf (70 µg/kg) is more neuroprotective than bmscs (2×105 number of bmscs). results of our study suggest that g-csf alone is more neuroprotective than bmscs.